1.Myopia Control with Bifocal Contact Lenses:?A Randomized Clinical Trial 2.The Role of Atropine Eye Drops in Myopia Control 4. Myopia Control: A Review 7. Efficacy of 1%?atropine?eye drops in retarding progressive axial myopia in Indian eyes 8.Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia 9.Current approaches to myopia control 10.Atropine?for the Prevention of Progression in Myopia - Data, Side Effects, Practical Guidelines 13. Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia. 18. The treatment of myopia with?atropine?and bifocals. A long-term prospective study 19. Inhibitory effects of apomorphine and?atropine?and their combination on myopia in chicks 20. The penetration and distribution of topical?atropine?in animal ocular tissues. 21. Treatment outcomes of?myopic?anisometropia with 1%?atropine: a pilot study 23. Does?atropine?use increase intraocular pressure in?myopic?children? 24. Atropine?use for the prevention of myopia progression 25. Allergic reactions to?atropine?eye drops for retardation of progressive myopia in children. 29. Maximum?atropine?dose without clinical signs or symptoms. 31. Atropine?and bifocals can slow the progression of myopia in children. 33. Prevention of myopia onset with 0.025%?atropine?in premyopic children 35. The long-term results of using low-concentration?atropine?eye drops for controlling myopia progression in schoolchildren. 37. Prevention of myopia progression with 0.05%?atropine?solution.   [更多]

具體要求： 你只需將我們要求的軟文發(fā)布到你的qq空間，騰訊qq級(jí)別要求為2個(gè)月亮及以上，qq空間活躍度高。即可獲得每篇5元的賞金。推廣賺錢就是這么簡(jiǎn)單！ 推廣要求： 1、要求所發(fā)qq空間的qq級(jí)別為2個(gè)月亮及以上，低于此級(jí)別的無效； 2、發(fā)布文章時(shí)要求內(nèi)容完整，工整有序； 3、同一篇文章一個(gè)qq空間只能發(fā)布一次，重復(fù)無效； 4、發(fā)布的文章不登陸可見，半月內(nèi)不能刪除； 5、同一篇文章可發(fā)布到多個(gè)qq空間，累計(jì)賞金； 6、一篇文章發(fā)布一個(gè)qq空間賞金為5元，滿50元即可提現(xiàn)； 7、發(fā)一個(gè)稿件就投一個(gè)標(biāo)，投標(biāo)時(shí)提供所發(fā)布qq空間的頁面鏈接，以便我們審核發(fā)放賞金。 發(fā)布文章見附件！   [更多]

飲片的切制規(guī)格，比如白頭翁藥典規(guī)定切薄片，請(qǐng)問這個(gè)是指切制的厚度，還是指經(jīng)過干燥等工序后，成品的片厚。   [更多]

1、American Conference of Governmental Industrial Hygienists TLVs and BEIs. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH, 2008, 2、內(nèi)容：Totsuka K，F(xiàn)urukawa M，F(xiàn)uruya N，et al. PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial （3）.45th Intersci Conf Antimicrob Agents Chemother（ICAAC）（Dec 16-19. Washington，D.C.），2005，Abst L-579標(biāo)題 PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial； 3、PK–PD analysis of tebipenem pivoxil in clinical trials for pediatric patients. Jpn J Chemother. 2009;57(S-1):186–91. 4、Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. González MA1, Straughan AB. 5、Single dose study of the bioequivalence of two sustained-release theophylline formulations. Contreras J, Pérez N, González R, Ontivero E, López M. Arzneimittelforschung. 1998 Mar;48(3):259-62. 6、National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information., AD277-689 7、Graul, A.; Castaner, J.; Atorvastatin Calcium. Drugs Fut 1997, 22, 9, 956. 8、Formulation And Evaluation of Topical Aceclofenac Gel Using Different Gelling Agent（JAPAN PATEL1*, BRIJESH PATEL1, HARDEEPSINGH BANWAIT1, KAUSHAL PARMAR1,MANISH PATEL2 Department of Pharmaceutics, Sat Kaival College of Pharmacy, Sarsa, Anand, Gujarat, India Nootan Pharmacy College, Visnagar, Gujarat, India） 9、NCCN pediatric neuroblastoma practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Dec;10(12):1813-22 10、Preliminary studies on toxic effects of some vulcanizing accelerators 11、Dose Dumping Dose dumping is an increased concern with drugs manufactured as modified-release (MR) formulations, that is, where drug   [更多]

亟需最新益母草歐洲藥典標(biāo)準(zhǔn)一份。不勝感激！   [更多]

標(biāo)題：尋求眼壓計(jì)的項(xiàng)目開發(fā)資源，尋求與您的合作 詳細(xì)要求：具備眼壓計(jì)開發(fā)技術(shù)，專利技術(shù)，謀求共同研發(fā)眼壓計(jì) 需求名稱：眼壓計(jì)項(xiàng)目資源 具體要求：這里列出您的需求 要求時(shí)間：請(qǐng)?jiān)?017年12月01日之前 交稿方式：直接點(diǎn)擊交稿在線交稿就是了，我會(huì)每天過來看的，謝謝各位藥智的戰(zhàn)友們   [更多]

5元一篇，QQ空間轉(zhuǎn)發(fā)醫(yī)藥文章（第一期） 具體要求： 你只需將我們要求的軟文發(fā)布到你的qq空間，騰訊qq級(jí)別要求為2個(gè)月亮及以上，即可獲得每篇5元的賞金。推廣賺錢就是這么簡(jiǎn)單！ 推廣要求： 1、要求所發(fā)qq空間的qq級(jí)別為2個(gè)月亮及以上，低于此級(jí)別的無效； 2、發(fā)布文章時(shí)要求內(nèi)容完整，工整有序； 3、同一篇文章一個(gè)qq空間只能發(fā)布一次，重復(fù)無效； 4、發(fā)布的文章不登陸可見，半月內(nèi)不能刪除； 5、同一篇文章可發(fā)布到多個(gè)qq空間，累計(jì)賞金； 6、一篇文章發(fā)布一個(gè)qq空間賞金為5元，滿50元即可提現(xiàn)； 7、發(fā)一個(gè)稿件就投一個(gè)標(biāo)，投標(biāo)時(shí)提供所發(fā)布qq空間的頁面鏈接，以便我們審核發(fā)放賞金。 發(fā)布文章見附件：   [更多]

請(qǐng)發(fā)至qq郵箱：978373564@qq.com   [更多]

20元求DSC2014 ascorbic acid\calcium ascorbate\levocarnitine\sodium ascorbate四個(gè)產(chǎn)品的標(biāo)準(zhǔn)文本。   [更多]

文拉法辛 USP 40 的藥典標(biāo)準(zhǔn)以及歐洲EP 9.0 。都查到發(fā)來可得賞金   [更多]